MuriPhys supports oncology research using patient-derived xenografts, orthotopic tumor models and study-specific drug administration. Materials, model readiness, controls and endpoints are defined with the sponsor.
Patient-Derived Xenograft (PDX) Models
PDX models are established from patient tumor material. Material provenance, access, engraftment requirements and study readiness are confirmed for the project. The established tumor cell lines listed below are related CDX resources, distinct from patient-derived PDX material.
Related cell-line resources for CDX studies
Cell identity, disease classification, provenance and availability are confirmed for the chosen study.
- Prostate cancer: LNCaP, PC-3, DU-145.
- Breast cancer: MCF-7, MDA-MB-231, MDA-MB-468, MDA-MB-453.
- Colorectal cancer: HT-29, HCT-116, COLO 205, SW620, SNU-C2B, KM12.
- Lung cancer: NCI-H460, NCI-H522, A549, DMS53.
- Melanoma: SK-MEL-2, A2058, A375.
- Epidermoid carcinoma: A431.
- Pancreatic cancer: MIA-PaCa-2, PANC-1.
- Ovarian cancer: OVCAR-3, SK-OV-3.
- Glioblastoma: U87-MG, LN-229, SF268, U251.
- Neuroepithelioma: SK-N-MC.
- Multiple myeloma: MM.1S, RPMI 8226, OPM-2.
- Chronic myeloid leukemia: K562.
- Acute myeloid leukemia: MOLM-13, MV4-11.
Animal Models - Nude Mice (Athymic Nude), SCID Mice, NSG Mice, NSG-HIS (Human Immune System models), BRGSF (Balb/c Rag2-/- IL2rg-/- SIRPα Tg). Contact us if you do not see your animal model.
Advanced Drug Administration & Serial Injections
We specialize in the following routes of administration:
Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), Intrathecal (IT), Intra Peritoneal (IP), Oral Gavage (PO), Topical, Slow-infusion and Continuous Infusions – supporting accurate systemic or localized therapeutic exposure.
Serial Injections – Enabling longitudinal drug administration studies to monitor treatment effects over time.
Quality Control: Mycoplasma Testing
Cell-line quality control includes mycoplasma testing to identify contamination. The testing plan, cell identity checks and acceptance criteria are defined for the study and documented with the work.
At MuriPhys, we are dedicated to accelerating oncology drug discovery with specialized preclinical solutions. Contact us today to discuss how we can support your oncology research!
Discuss the tumor model, treatment strategy, readouts and study stage with our oncology team. We will work with you to define the methods, controls, deliverables, timing and budget.